Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-γ and interleukin-12

Journal of Surgical Research

Volumn 116, Issue 1, 2004, Pages 64-69

  Hiramoto, Jade S ^a   Tsung, Kangla ^a   Bedolli, Melanie ^a   Norton, Jeffrey A ^a   Hirose, Ryutaro ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dendritic cell; IL 12; Interferon ; Tumor vaccine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPECIES COMPARISON; SPLEEN CELL; TUMOR REJECTION; VACCINATION; WILD TYPE;

EID: 0346460325     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2003.09.006     Document Type: Article

References (25)

1. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:1991;271.
2. Kugler A., Stuhler G., Walden P., Zoller G., Zobywalski A., Brossart P., Trefzer U., Ullrich S., Muller C.A., Becker V., Gross A.J., Hemmerlein B., Kanz L., Muller G.A., Ringert R.H. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6:2000;332.
3. Bellone M., Cantarella D., Castiglioni P., Crosti M.C., Ronchetti A., Moro M., Garancini M.P., Casorati G., Dellabona P. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165:2000;2651.
4. Klein C., Bueler H., Mulligan R.C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191:2000;1699.
5. McArthur J.G., Mulligan R.C. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J. Immunother. 21:1998;41.
6. Herr W., Ranieri E., Olson W., Zarour H., Gesualdo L., Storkus W.J. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood. 96:2000;1857.
7. Tsung K., Meko J.B., Peplinski G.R., Tsung Y.L., Norton J.A. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158:1997;3359.
8. Le H.N., Lee N.C., Tsung K., Norton J.A. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J. Immunol. 167:2001;6765.
9. Lee N.C., Tsung K., Norton J.A. Production of interferon-gamma by tumor-sensitized T cells is essential for interleukin-12-induced complete tumor eradication. Surgery. 132:2002;365.
10. Macatonia S.E., Hosken N.A., Litton M., Vieira P., Hsieh C.S., Culpepper J.A., Wysocka M., Trinchieri G., Murphy K.M., O'Garra A. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J. Immunol. 154:1995;5071.
11. Koch F., Stanzl U., Jennewein P., Janke K., Heufler C., Kampgen E., Romani N., Schuler G. High level IL-12 production by murine dendritic cells Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10 . J. Exp. Med. 184:1996;741.
12. Ohteki T., Fukao T., Suzue K., Maki C., Ito M., Nakamura M., Koyasu S. Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J. Exp. Med. 189:1999;1981.
13. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245.
14. Schnell S., Young J.W., Houghton A.N., Sadelain M. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity implications for the clinical use of dendritic cells . J. Immunol. 164:2000;1243.
15. Fields R.C., Shimizu K., Mule J.J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 95:1998;9482.
16. Fallarino F., Uyttenhove C., Boon T., Gajewski T.F. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int. J. Cancer. 80:1999;324.
17. Bianchi R., Grohmann U., Belladonna M.L., Silla S., Fallarino F., Ayroldi E., Fioretti M.C., Puccetti P. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J. Immunol. 157:1996;1589.
18. Tatsumi T., Takehara T., Kanto T., Miyagi T., Kuzushita N., Sugimoto Y., Jinushi M., Kasahara A., Sasaki Y., Hori M., Hayashi N. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma. Cancer Res. 61:2001;7563.
19. Grohmann U., Bianchi R., Belladonna M.L., Vacca C., Silla S., Ayroldi E., Fioretti M.C., Puccetti P. IL-12 acts selectively on CD8 alpha-dendritic cells to enhance presentation of a tumor peptide in vivo. J. Immunol. 163:1999;3100.
20. Grohmann U., Bianchi R., Ayroldi E., Belladonna M.L., Surace D., Fioretti M.C., Puccetti P. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158:1997;3593.
21. Ribas A., Amarnani S.N., Buga G.M., Butterfield L.H., Dissette V.B., McBride W.H., Glaspy J.A., Ignarro L.J., Economou J.S. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene Ther. 9:2002;875.
22. Noguchi Y., Richards E.C., Chen Y.T., Old L.J. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA. 92:1995;2219.
23. Portielje J.E., Gratama J.W., van Ojik H.H., Stoter G., Kruit W.H. IL-12 A promising adjuvant for cancer vaccination . Cancer Immunol. Immunother. 52:2003;133.
24. Iwashita Y., Tahara K., Goto S., Sasaki A., Kai S., Seike M., Chen C.L., Kawano K., Kitano S. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol. Immunother. 52:2003;155.
25. Marten A., Renoth S., Heinicke T., Albers P., Pauli A., Mey U., Caspari R., Flieger D., Hanfland P., Von Ruecker A., Eis-Hubinger A.M., Muller S., Schwaner I., Lohmann U., Heylmann G., Sauerbruch T., Schmidt-Wolf I.G. Allogeneic dendritic cells fused with tumor cells Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma . Hum. Gene Ther. 14:2003;483.